TapewireFind a company

person · Reporting owner

Nazzi Gianfranco

Disclosed activity across 1 company

Tapewire entity
141703
SEC CIK
0001725018

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063EVP, International MarketsMarch 04, 2021March 08, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date March 04, 2021 · Filed March 08, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect0 Last balance in matching sequence After 2021-03-04 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2021-03-04 · Grant · Acquired 12,935 · Balance 12,935

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Row 2 · 2021-03-04 · Sale · Disposed 12,935 · Balance 0

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Restricted Share UnitsSEC Table II · derivative / convertible securityDirect25,870 Reported balance After 2021-03-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-03-04 · Exercise / conversion · Disposed 12,935 · Balance 25,870

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 04, 2021 Filed Mar 8, 2021 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 12,935 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018524 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,870

Underlying: Ordinary Shares · 12,935 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 12,935 $10.58 $136,909.21
Disclosure

SEC source: 0001209191-21-018524 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantOrdinary Shares 12,935 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-018524 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,935

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2021 Filed Mar 4, 2021 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,400 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-017761 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2021 Filed Mar 4, 2021 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 1,400 $10.88 $15,231.44
Disclosure

SEC source: 0001209191-21-017761 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.840 to $10.915, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2021 Filed Mar 4, 2021 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,400 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-017761 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 60,410.357 $10.88 $657,240.52
Disclosure

SEC source: 0001209191-21-015847 · doc4.xml · nonDerivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.84 to $10.91, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 15,177 $10.85 $164,684.11
Disclosure

SEC source: 0001209191-21-015847 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,410.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.775 to $11.005, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2021 Filed Mar 2, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,177 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-015847 · doc4.xml · derivative · entry 4

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,534

Underlying: Ordinary Shares · 15,177 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2021 Filed Mar 2, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 15,177 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-015847 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,587.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 11,941 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-009637 · doc4.xml · derivative · entry 5

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,941

Underlying: Ordinary Shares · 11,941 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 17,480 $12.72 $222,361.33
Disclosure

SEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 4

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,410.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 4,155 $12.72 $52,855.34
Disclosure

SEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,890.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantOrdinary Shares 50,260 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,045.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.

F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 11,941 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,785.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:36 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 874 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-020164 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.

F6 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:36 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 345 $7.17 $2,474.13
Disclosure

SEC source: 0001209191-20-020164 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,844.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.2000, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:36 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 874 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-020164 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,189.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2020 Filed Mar 5, 2020 13:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,399 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-016460 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Ordinary Shares · 1,399 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2020 Filed Mar 5, 2020 13:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 548 $11.77 $6,447.60
Disclosure

SEC source: 0001209191-20-016460 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,315.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7300 to $11.8100, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2020 Filed Mar 5, 2020 13:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,399 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-016460 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,863.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 12:16 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 60,711 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-014852 · doc4.xml · derivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,711

Underlying: Ordinary Shares · 60,711 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024.

F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 10, 2020 Filed Feb 11, 2020 12:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 4,155 $12.24 $50,864.26
Disclosure

SEC source: 0001209191-20-008165 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,464.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2400 to $12.2450, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2020 Filed Feb 11, 2020 12:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 11,941 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-008165 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,882

Underlying: Ordinary Shares · 11,941 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2020 Filed Feb 11, 2020 12:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 11,941 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-008165 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,619.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
September 18, 2019 Filed Sep 20, 2019 11:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 2,638 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-050265 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,638 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019.

F5 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
September 18, 2019 Filed Sep 20, 2019 11:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 962 $7.82 $7,523.13
Disclosure

SEC source: 0001209191-19-050265 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,678.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.81 to $7.84, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
September 18, 2019 Filed Sep 20, 2019 11:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 2,638 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-050265 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,640.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 18, 2019 Filed Mar 19, 2019 12:17 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 320 $16.64 $5,326.27
Disclosure

SEC source: 0001209191-19-020162 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,002.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.6400 to $16.6516, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2019 Filed Mar 19, 2019 12:17 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 872 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-020162 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 874

Underlying: Ordinary Shares · 872 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.

F5 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2019 Filed Mar 19, 2019 12:17 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 872 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-020162 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,322.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 12, 2019 Filed Mar 14, 2019 11:36 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 883 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-019330 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 883 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019.

F5 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 12, 2019 Filed Mar 14, 2019 11:36 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 325 $15.69 $5,099.19
Disclosure

SEC source: 0001209191-19-019330 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,450.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.670 to $15.705, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 12, 2019 Filed Mar 14, 2019 11:36 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 883 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-019330 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,775.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2019 Filed Mar 5, 2019 13:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 512 $16.88 $8,644.81
Disclosure

SEC source: 0001209191-19-016097 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,892.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.1316, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2019 Filed Mar 6, 2019 12:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 38,805 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-017233 · doc4.xml · derivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,805

Underlying: Ordinary Shares · 38,805 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2019 Filed Mar 5, 2019 13:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,399 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-016097 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Ordinary Shares · 1,399 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2019 Filed Mar 5, 2019 13:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,399 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-016097 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,404.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 20:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 2,638 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-051778 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,638

Underlying: Ordinary Shares · 2,638 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019.

F5 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 20:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 1,379 $23.69 $32,669.89
Disclosure

SEC source: 0001209191-18-051778 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,005.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.680 to $23.720, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 20:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 2,638 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051778 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,384.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 19, 2018 Filed Mar 20, 2018 20:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 457 $17.89 $8,176.64
Disclosure

SEC source: 0001209191-18-020862 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,746.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.87 to $17.92, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2018 Filed Mar 20, 2018 20:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 872 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-020862 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,746

Underlying: Ordinary Shares · 872 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.

F5 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2018 Filed Mar 20, 2018 20:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 872 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-020862 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,203.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 12, 2018 Filed Mar 14, 2018 20:31 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 880 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-019565 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 883

Underlying: Ordinary Shares · 880 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019.

F5 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 12, 2018 Filed Mar 14, 2018 20:31 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 461 $19.50 $8,988.58
Disclosure

SEC source: 0001209191-18-019565 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,331.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.49 to $19.5107, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 12, 2018 Filed Mar 14, 2018 20:31 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 880 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-019565 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,792.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2018 Filed Mar 6, 2018 21:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Tax withholdingOrdinary Shares 732 $19.28 $14,112.96
Disclosure

SEC source: 0001209191-18-017227 · doc4.xml · nonDerivative · entry 2

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,912.357

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2018 Filed Mar 6, 2018 21:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,399 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-017227 · doc4.xml · derivative · entry 3

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,198

Underlying: Ordinary Shares · 1,399 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2018 Filed Mar 6, 2018 21:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,399 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-017227 · doc4.xml · nonDerivative · entry 1

Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,644.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.